Alembic Pharma gets USFDA EIR for Oncology Injectable Formulation Facility at Panelav
Advertisement
Vadodara: Drugmaker Alembic Pharma has recently announced that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its Oncology Injectable Formulation Facility at Panelav.
The facility was inspected from 4 th October, 2022 to 14th October, 2022.
"This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our Oncology Injectable Formulation Facility at Panelav during the period from 4th October, 2022 to 14th October, 2022," Alembic Pharma stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.